As 2025 comes to a close, it is clear that this has been a defining year for Glooko and for the broader evolution of diabetes care. Following the close of our Series F, we entered the year with a clear focus: deliver on our strategy, expand our global impact, and continue building technology that helps make diabetes care more connected, actionable, and human.

Accelerating our Mission through Strategic Leadership and a Connected Care Continuum

Over the past year, we reached several important milestones in support of that goal. We expanded our capabilities through the acquisition of Monarch Medical Technologies and its EndoTool Glucose Management System, bringing together complementary capabilities across outpatient and inpatient diabetes and glycemic management.

We strengthened our ecosystem with the launch of our Abbott FreeStyle Libre integration in the U.S., helping ensure that critical glucose data can flow more seamlessly to people with diabetes and their care teams.

We also reinforced our clinical leadership with the appointment of Mark Clements, M.D., Ph.D., as Chief Medical and Strategy Officer, underscoring our commitment to evidence-based innovation and strong clinical partnership.

Driving Digital Health Adoption in EMEA

We also saw meaningful traction across geographies and care settings.

In EMEA, we continued to expand our presence as health systems look for scalable, interoperable digital solutions to support diabetes care. At the same time, Glooko XT, our remote monitoring solution available only in France, introduced new features and strengthened its gestational diabetes management capability, an area where timely insights and coordinated care are critical for both maternal and fetal outcomes. These areas of momentum reflect the growing demand for digital tools that can support diverse patient populations and clinical workflows.

Further Enhancing our Diabetes Management Platform to Improve Care

On the product front, we continued to invest in tools designed for the realities of care delivery.

The launch of the new Glooko clinic dashboard marked an important step forward in helping clinics and health systems move beyond raw data to clearer insights, enabling more informed, timely decisions at the point of care. Across the organization, we remained focused on bringing teams together around a shared mission and shared standards, ensuring that our growth continues to be purposeful and aligned.

A reality faced by care teams each day is the need for timely, actionable data within existing clinical workflows. That’s why we invested further into our EHR capabilities this year and joined the Epic Showroom to make it easier for hospitals and health systems to seamlessly integrate their EHR with Glooko, helping reduce clinician burnout and optimize clinical workflows.

The Glooko Mobile App for people with diabetes also continued to innovate in 2025 with a redesigned food tracker for more insightful nutrition data and insights, revised insulin cards for more clarity, and viewable GLP-1 doses. These enhancements enable care teams to make more informed and timely treatment decisions between appointments using their patients’ health data – all viewable in one place.

How the U.S. Healthcare System is Moving Toward Data-Driven, Accountable Diabetes Care

These milestones matter, but they are occurring against a broader backdrop of change in healthcare that strongly validates this direction. The latest American Diabetes Association’s Standards of Care reinforce what clinicians and people with diabetes have long understood: technology-enabled management and data-driven insights are now foundational to delivering high-quality diabetes care.

At the same time, policy initiatives such as the CMS ACCESS program signal a growing emphasis on interoperability, data liquidity, and the responsible use of health data to improve outcomes at scale.

Together, these shifts point to a future in which diabetes care is increasingly proactive rather than reactive, and where data is not simply collected, but translated into meaningful action.

Regulatory momentum is reinforcing the importance of consistent, evidence-based glycemic management across care settings. CMS’s upcoming electronic clinical quality measure (eCQM) requirements for inpatient glycemic management, expected to take effect in 2026, reflect a growing emphasis on standardization, measurement, and accountability in hospital-based diabetes care. Solutions like EndoTool are at the forefront of this shift, helping health systems operationalize best practices, support clinical decision-making, and drive more reliable glycemic outcomes at scale.

For healthcare providers and care teams, this evolution brings both opportunity and urgency. As care becomes more continuous and data-rich, success depends on having tools, like Glooko’s EHR integrations, that reduce complexity, surface what matters most, and fit naturally into clinical workflows. The goal is not more data for its own sake, but clearer insight that supports better decisions and more personalized care.

For health systems, the focus is expanding to population-level impact. Managing chronic disease across diverse populations requires platforms that enable earlier intervention, more consistent care, and coordination across settings. Interoperable digital solutions, like Glooko, are becoming essential infrastructure for balancing quality, efficiency, and cost in an increasingly complex care environment.

Leveraging Scalable Healthcare Technology to Deliver Consistent Diabetes Care Around the World

Globally, the stakes are even higher. Diabetes prevalence continues to rise across regions with very different healthcare resources and delivery models. Scalable digital health solutions offer a path to extend evidence-based care, support clinicians, and bring greater consistency to diabetes management worldwide. As global standards and policies evolve, technology will play a central role in enabling more equitable access to high-quality care.

The Road Ahead for Glooko

Looking ahead, our focus at Glooko remains clear. We will continue investing in platforms that turn diabetes data into insight, insight into action, and action into better outcomes. We will deepen partnerships across the ecosystem and stay closely aligned with clinicians, health systems, and people with diabetes as their needs continue to evolve.

2025 was a year of momentum for Glooko. More importantly, it reinforced why our mission matters. As the future of diabetes care continues to take shape, we are energized by the opportunity to help lead the way.

EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions.

We are proud to share that Glooko has been recognized by The Healthcare Technology Report as one of the Top 50 Healthcare Technology Companies of 2025. This honor reflects the progress we are making toward building a more connected, personalized, and accessible future for people with diabetes and the clinicians who support them.

Each year, this list highlights organizations that are shaping the trajectory of healthcare through innovation and meaningful impact. For Glooko, this recognition reinforces the work taking place across our teams to simplify the complexity of diabetes care. Whether it is bringing data from devices into a single platform, supporting timely clinical decision making, or expanding digital tools that help people manage their diabetes with confidence, our mission has remained constant. We aim to improve patient outcomes through connected care platforms that work in the real world.

This award also reflects how far we have come in strengthening our portfolio. From the continued evolution of the Glooko platform, to the future integration of the inpatient insulin dosing technology of EndoTool, developed by Monarch Medical Technologies, a Glooko Company, to our partnerships that expand clinical value and accessibility, we are building an innovative approach to diabetes management that spans the full care journey. These advancements are the direct result of our teams’ expertise and commitment to the people who rely on our products every day.

Most importantly, this recognition is a reminder of why we do this work. Behind every data point is a person managing a lifelong condition while balancing the demands of life, family, and care. Our responsibility is to meet them where they are with tools that are intuitive, reliable, and informed by real clinical needs.

We are honored to be included among so many forward-thinking healthcare technology leaders. As we look to 2026, we remain focused on delivering solutions that empower clinicians, support health systems, and make life better for people with diabetes around the world.

EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions.

Today marks an important milestone in our mission to transform diabetes care. I am excited to share that Glooko has acquired Monarch Medical Technologies, creators of the EndoTool® Glucose Management System.

With this acquisition, Glooko is positioned to become the only diabetes management company with the potential to connect the full continuum of care — from home to hospital and back again. By bringing together EndoTool’s proven inpatient insulin dosing technology with Glooko’s leading outpatient platform, we aim to create a future where care is seamless, safer, and more supportive for both people living with diabetes and healthcare providers.

For patients, this means fewer disruptions as they move between settings, reduced risk of dangerous glycemic events, and more confidence that their care is connected. For healthcare providers, it means access to tools that simplify complex insulin management, standardize protocols, and free up time to focus on what matters most, which is caring for people.

This step also sets the foundation for Glooko’s future: using data and AI to help clinicians anticipate risks earlier, personalize care at scale, and improve outcomes under value-based models. By aligning advanced technology with clinical guidelines and EHR workflows, we can help hospitals and health systems deliver higher-quality care while lowering costs.

Our mission has always been clear: to simplify diabetes management, strengthen connections across the care team, and improve lives. This acquisition represents an important stride toward that vision.

Together, we are building a future where diabetes care is more connected, proactive, and patient-centered than ever.

EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions.